Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Health Care Select Sector SPDR Fund — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B), while Health Care Select Sector SPDR Fund trades at $168.16 (market cap $43.48B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.9× Health Care Select Sector SPDR Fund's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| VRTX | XLV | |
|---|---|---|
Market Cap | $127.55B | $43.48B |
Volume | 1,487,944 | 11,121,431 |
Sector | Health | — |
52-Week High | $557.96 | $175.68 |
52-Week Low | $407.37 | $141.95 |
Typical Hold Time | 120 Days | 100 Days |
Enterprise Value | $121.68B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
XLV trades at $168.81, up 1.03% today, with a bullish technical signal driven by moving averages. The ETF holds 61 healthcare stocks from the S&P 500, offering broad sector exposure at a low 0.08% expense ratio. Recent news highlights its defensive appeal amid market volatility and potential Fed rate hikes, with articles comparing it favorably to peers like IBB and PJP on cost and diversification.
Outlook is positive given healthcare's defensive growth profile and XLV's cost efficiency, but risks include political uncertainty from midterm elections and sector-specific volatility from drug trial outcomes. Wall Street sentiment is constructive, with the ETF near key resistance at $170.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
